AIG-backed cancer and genetic disease developer BridgeBio Pharma has filed for a $225m initial public offering on the Nasdaq Global Market.

US-based genetic disease drug developer BridgeBio Pharma filed on Friday to raise up to $225m in an initial public offering that will enable insurance and financial services group AIG to exit. BridgeBio is developing treatments for Mendelian diseases, which are caused by defects in a single specific gene, in addition to forms of cancer that…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.